Concepedia

Sam Agresta

SA

Statistics

Publications

22

Citations

5.1K

H-Index

20

Active since

2013

Affiliations

Agios Pharmaceuticals (United States)(Current)

Massachusetts General Hospital

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Sam Agresta is an author at Agios Pharmaceuticals (United States) specializing in medicine, pathology, and oncology.

Top concepts

Publications per year

2013–2020

22

Publications

22

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.4K citations · Full text

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 789 citations

Characteristics, clinical outcome, and prognostic significance of <scp>IDH</scp> mutations in <scp>AML</scp>

Courtney D. DiNardo, Farhad Ravandi, Sam Agresta et al. · American Journal of Hematology · 2015 · 300 citations · Full text

, , +15

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek, Muriel D. David, Alison Kennedy et al. · Nature Medicine · 2018 · 193 citations · Full text

, , +11

1–5 of 22